Taking Toll of Toll-Like Receptors

Courtesy of Alan Aderem  BAR-CODED BACTERIA: Combined activation of Toll-Like Receptors (TLRs) produces different specific responses. In this example, Microbe 1 activates TLRs 4 and 5, and is therefore likely to be a Gram-negative, flagellated bacterium. Microbe 2 activates TLR 5 and TLR 2/6, and is therefore likely to be Gram-positive and flagellated. Because of slightly different specificities, Microbe 3 would elicit a different response. Twas a head-scratcher: Twelve years ago, resear

Written byKaren Young Kreeger
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Twas a head-scratcher: Twelve years ago, researchers found that a receptor, known for its role in a fruit fly dorsoventral patterning called Toll, was related to an important mammalian immune receptor called interleukin-1 (IL-1), a pro-inflammatory cytokine.1 "How could this be?" recalls biochemistry professor Luke O'Neill, Trinity College, Dublin. "We have IL-1, which is inflammatory, and Toll, which is developmental.... Why would they be so similar?" But then it was shown in the adult fly that Toll has a role in antifungal defense.2

Since 1996, numerous researchers have investigated Toll-like receptors (TLRs) in mammals, which are involved in innate immunity, the body's first response to infection. Innate immunity is inborn; acquired immunity, which involves such downstream immune system components as dendritic cells and antigens, is obtained through lifelong contact with pathogens.

Four papers in 2001 added more pieces to the ever-evolving, complex TLR story.3-6 These researchers began detailing a clearer ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies